Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial

Autor: Fouad Chouairi, BS, Justin Pacor, MD, P. Elliott Miller, MD, Michael A. Fuery, MD, Cesar Caraballo, MD, Sounok Sen, MD, Eric S. Leifer, PhD, G. Michael Felker, MD, MHS, Mona Fiuzat, PharmD, Christopher M. O’Connor, MD, James L. Januzzi, MD, Daniel J. Friedman, MD, Nihar R. Desai, MD, MPH, Tariq Ahmad, MD, MPH, James V. Freeman, MD, MPH, MS
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 2, Pp 447-455 (2021)
Druh dokumentu: article
ISSN: 2542-4548
DOI: 10.1016/j.mayocpiqo.2021.02.005
Popis: Objective: To evaluate effects of atrial fibrillation (AF) on cardiac biomarkers and outcomes in a trial population of patients with heart failure (HF) with reduced ejection fraction treated with optimal guideline-directed medical therapy. Methods: We performed a secondary analysis of 894 patients in the Guiding Evidence-Based Therapy Using Biomarker-Intensified Treatment in Heart Failure (GUIDE-IT) trial (January 2013–July 2016). Patients were stratified by AF status and compared with regard to guideline-directed medical therapy use, longitudinal levels of N-terminal pro–B type natriuretic peptide (NT-proBNP), and outcomes including HF hospitalization and mortality. Results: After adjustment, AF was associated with a significant increase in the risk of HF hospitalization or cardiovascular death (hazard ratio, 1.28; 95% CI, 1.02 to 1.61; P=0.04) and HF hospitalization (hazard ratio, 1.31; 95% CI, 1.02 to 1.68; P=.03) but with no difference in mortality during a median 15 months of follow-up. There were no significant differences in medication treatment between those with and those without AF. At 90 days, a higher proportion of patients with AF (89.4% vs 81.5%; P=.002) had an NT-proBNP level above 1000 pg/mL (to convert NT-proBNP values to pmol/L, multiply by 0.1182), and AF patients had higher NT-proBNP levels at all time points through 2 years of follow-up. Conclusion: Among patients with HF with reduced ejection fraction, prevalent AF was associated with higher NT-proBNP concentrations through 2 years of follow-up and higher risk for HF hospitalization despite no substantial differences in medical therapy.
Databáze: Directory of Open Access Journals